IRVINE, CA--(Marketwire - Aug 16, 2012) - Itonis, Inc. (
Dr. Hensley commented, "We had wide success upon creating the Zicam® Cold Remedy and I believe that similar preparations can be created to treat many other common ailments. We plan to launch several products into this derivative pharmaceutical category over the coming months. It is exciting to be a part of this new venture and we plan to move expeditiously into the marketing of the formulations that we plan to announce."
Dr. Hensley has joined Itonis as President of its Itonis Pharmaceuticals division that Itonis expects to convert into a new subsidiary. The mission of Itonis Pharmaceuticals is to create science-based products to alleviate symptoms of common ailments and chronic conditions.
About Itonis Pharmaceuticals
Itonis Pharmaceuticals, a new division of Itonis, Inc., is headed by Charles Hensley, Ph.D. to create over-the-counter and prescription homeopathic products that better people's lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of Geltech, LLC, the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.
About Itonis, Inc.
Itonis, Inc. (the "Company") was incorporated in the state of Nevada on July 5, 2005 under the name of Kenshou, Inc., which later changed to Itonis, Inc. on December 2, 2005. For more information, please visit www.itonisholdings.com.
Safe Harbor:
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.
Contact Information:
Contact:
Michael Biddick
(949) 529-1588